A prospective, multicenter, open label single arm Phase IV clinical trial to assess safety of ImbruvicaTM (Ibrutinib capsules 140 mg) in Indian patients with chronic lymphocytic leukemia or mantle cell lymphoma who have received at least one prior therapy or chronic lymphocytic leukemia with 17p deletion

Johnson and Johnson Private Limited0 个研究点目标入组 75 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•1. Chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) participants being newly initiated on Imbruvica treatment (ibrutinib capsule 140 milligram [mg]) based on independent clinical judgment of treating physicians as per locally approved prescribing information
•2. Must give a written informed consent indicating that they understand the purpose and are willing to participate in the study and allowing data collection and source data verification in accordance with regulatory requirements

•1. Participants who are not eligible to receive Imbruvica as per the locally approved prescribing information
•2.Participants participating or planning to participate in any interventional drug trial during the course of this study

发起方